Skip to main content
SpringerLink
Log in

Is Renal Protection with Calcium Antagonists Possible?

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Organ protection is the main goal in the treatment of high blood pressure. Consequently, this protective capacity should be one of the main characteristics of any drug used in the treatment of hypertension. A renal protective agent should protect the kidney from intrinsic renal vasoconstrictors and exogenous agents, and should also protect, or at least delay, the decline in renal function in the presence of renal insufficiency, by mechanisms other than increasing glomerular filtration pressure. Verapamil protects mesangial cells from the reduction in surface area induced by endothelin in vitro. In human subjects, it minimises the renal impairment provoked by the administration of cisplatin, and in mice it protects superficial cortical blood flow from the vasoconstriction elicited by cyclosporin. Finally, verapamil may protect from glomerulosclerosis as a result of its capacity to inhibit mesangial cell replication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agatstein EH, Fairer JH, Kaplan LM, Randazzo RF, Glassock RJ, et al. The effect of verapamil in reducing the severity of acute tubular necrosis in canine renal autotransplants. Transplantation 44: 355–357, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bauer JH, Reams G. Short- and long-term effects of calcium entry blockers on the kidney. American Journal of Cardiology 59: 66A–71A, 1987

    Article  PubMed  CAS  Google Scholar 

  • Boero R, Quarello F, Guarena C, Piccoli G. Verapamil in arterial hypertension with renal disease. Nephron 44: 80, 1986

    Article  PubMed  CAS  Google Scholar 

  • Eiskjaer H, Pedersen EB, Rasmussen LM, Jesperen B. Sustained release verapamil in renal hypertension. European Journal of Clinical Pharmacology 33: 549–555, 1988

    Article  PubMed  CAS  Google Scholar 

  • Harris D, Hammond WS, Burke TJ, Schrier RW. Verapamil protects against progression of experimental chronic renal failure. Kidney International 31: 41–46, 1987

    Article  PubMed  CAS  Google Scholar 

  • Kubo SH, Cody RJ, Covit AB, Feldschuh J, Laragh JH. The effects of verapamil on renal blood flow, renal function, and neurohormonal profiles in patients with moderate to severe hypertension. Journal of Clinical Hypertension 3: 38S–46S, 1986

    Google Scholar 

  • Leonetti G, Sala C, Bianchini C, Terzoli L, Zanchetti A. Anti-hypertensive and renal effects of orally administered verapamil. European Journal of Clinical Pharmacology 18: 375–382, 1980

    Article  PubMed  CAS  Google Scholar 

  • López-Farré A, Montañés I, Fernández-Cruz A, López-Novoa JM. Verapamil blunts the effect of endothelin on renal function in rats. Medical Science Research 18: 323–324, 1990

    Google Scholar 

  • Macías-Núñez JF, García Iglesias C, Santos J, Sanz E, López-Novoa JM. Influence of plasma renin content, intrarenal angiotensin II, captopril and calcium channel blockers on the vasoconstriction and renin release promoted by adenosine in the kidney. Journal of Laboratory and Clinical Medicine 106: 562–567, 1985

    PubMed  Google Scholar 

  • Nakaki T, Nakayama M, Yamamoto S, Kato R. Endothelin-mediated stimulation of DNA synthesis in vascular smooth muscle cells. Biochemical Biophysical Research Communications 158: 880–883, 1989

    Article  CAS  Google Scholar 

  • Offerman JJG, Meijer S, Sleijfer DTh, Mulder NH, Donker AJM, et al. The influence of verapamil on renal function in patients treated with cisplatin. Clinical Nephrology 24: 249–255, 1985

    PubMed  CAS  Google Scholar 

  • Rahn KH, Van Bortel LM, Mooy JM. The use of calcium antagonists in patients with renal failure. Journal of Hypertension 5(Suppl. 4): 67–69, 1987

    Article  Google Scholar 

  • Rooth P, Davidson I, Diller K, Taljedal IB. Protection against cyclosporine-induced impairment of renal microcirculation by verapamil in mice. Transplantation 45: 433–437, 1988

    Article  PubMed  CAS  Google Scholar 

  • Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. American Journal of Pathology 79: 95, 1975

    PubMed  CAS  Google Scholar 

  • Sorensen SS, Thomsen OO, Danielsen H, Pedersen EB. Effect of verapamil on renal plasma flow, glomerular filtration rate, plasma angiotensin II, aldosterone and arginine vasopressin in essential hypertension. European Journal of Clinical Pharmacology 29: 257–261, 1985

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, University of Salamanca, Salamanca, Spain

    P. García-Cosmes, A. Mortezo, J. M. López-Novoa &  J. F. Macías-Núñez

Authors
  1. P. García-Cosmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Mortezo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. López-Novoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. F. Macías-Núñez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

García-Cosmes, P., Mortezo, A., López-Novoa, J.M. et al. Is Renal Protection with Calcium Antagonists Possible?. Drugs 44 (Suppl 1), 99–102 (1992). https://doi.org/10.2165/00003495-199200441-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199200441-00018

Keywords

Search

Navigation